Questions about our research, subscription options, or just want to say hello — drop us a line and we'll get back to you within one business day.
Use the topic chips below to pre-fill the subject, or describe your question directly.
Thanks for reaching out. A member of the ApexLens team will reply to within one business day.
For questions about our research, methodology, or editorial coverage.
hello@apexlenscapital.comHelp with your subscription, payment issues, or plan changes.
support@apexlenscapital.comInterview requests, commentary, or licensing inquiries for journalists and producers.
press@apexlenscapital.comApexLens Capital LLC
340 Madison Avenue, Suite 1200
New York, NY 10173
Mon – Fri, 9:00 AM – 6:00 PM ET
Closed on U.S. market holidays
Get our weekly research brief delivered every Sunday morning — free forever.
No. ApexLens Capital is an independent research publisher, not a registered investment adviser (RIA). Our content is for informational and educational purposes only and does not constitute personalized investment advice. Please consult a licensed financial professional before making investment decisions.
We publish our weekly newsletter every Sunday morning with macro commentary and new or updated picks. Deep-dive articles are published 2–3 times per month. Breaking market notes are sent when a covered company reports earnings or a significant development occurs.
All analyst disclosures are included at the bottom of every research note. We require analysts to disclose any personal positions in covered securities. We do not allow analysts to trade a security within 72 hours before or after publishing research on it.
Our price targets are 12-month forward estimates derived from a blended valuation model including discounted cash flow (DCF), comparable company multiples, and historical trading range analysis. Targets are reviewed and updated whenever a company reports quarterly earnings.
Brief quotes with attribution to ApexLens Capital and a link to the original article are permitted for editorial and educational use. Full reproduction of our research notes, picks lists, or premium reports is not permitted without written consent. Contact our press team for licensing inquiries.
No. ApexLens Capital does not accept advertising, sponsored content, broker referral fees, or payments from companies we cover. Our revenue comes exclusively from subscriptions. This structure is fundamental to our editorial independence.